Frame
Repair is a sequence, not “more myelin”
Oligodendrocyte precursor cells are recruited, then differentiate, then wrap axons, then compact a cholesterol-rich membrane. Failure can happen at any step.
Recorded
What's the stats with statins?
with guests: “Matthew” @Spare_Monkeys
Do you know someone who has been acting off past age 45? No promises. A conversation on whether statins may be contributing to brain deterioration.
Resources
A Brief Statin History and Remyelination Repair Index
Where statins came from, why people argue about them, and then the searchable notes. Tags are documented, plausible, or weak. This is not medical advice and not a diagnosis.
Statin history at a glance
- Discovery
- Akira Endo isolated compactin (mevastatin) from the mold Penicillium citrinum at Sankyo in Tokyo, July 1973.Endo, 2010
- First on the shelf
- Merck’s lovastatin (Mevacor) was the first statin the FDA approved, in 1987. Compactin itself never became a drug.Endo, 2010Drugs@FDA, NDA 019643
- 1980 dog study
- Endo wrote that Sankyo stopped compactin after dogs given 100–200 mg/kg/day developed lymphomas. None appeared at 20 mg/kg/day. That is his published account of the halt, not a human finding.Endo, 2010Endo, Lasker lecture, 2008
- Trials people cite
- 4S (1994), WOSCOPS (1995), CARE (1996), LIPID (1998), AFCAPS/TexCAPS (1998), and the CTT meta-analyses (2005, 2010). Outcomes are in those papers, not restated here.
- Guideline panels
- The Associated Press reported in 2004 that 8 of 9 members of the NCEP cholesterol panel had undisclosed industry ties. The BMJ reported in 2013 that 8 of 15 ACC/AHA panel members had industry ties. TIME counted 7. Ties are a disclosure issue. They are not proof the recommendations were bought.AP via Los Angeles Times, 2004BMJ 2013
- Money
- Lipitor was the top-selling drug in 2006, about $12.9 billion. In 2009 Pfizer settled a Department of Justice case for $2.3 billion. Lipitor was one of nine drugs named in the civil kickback allegations. That settlement was not a finding, and it was not a Lipitor-only case. A search for a Lipitor-specific prescribing incentive did not turn up a document.DOJ announcementForbes, 2006
- Cases
- No statin-specific Department of Justice or FTC case turned up. Nearby items are that Pfizer settlement, a 2009 Vytorin state attorneys general settlement about delayed trial results, and Lipitor antitrust litigation about generic delay. None of those is a myelin case.
- Risk calculator
- Critics say the 2013 Pooled Cohort Equations overestimate who should get a statin. How large that overestimate is remains disputed.Ridker and Cook, Lancet 2013
- 2012 FDA label
- The FDA added language on memory loss and confusion. It was not a boxed warning. Trial results on cognition are on the statins card in the index, not repeated here.FDA safety communication, archived
- The water remark
- In 2004, at a Heart UK debate, Dr John Reckless moved that “statins should be put in the drinking water.” It was a debate motion about undertreatment, not a policy or a government proposal.BBC News, 2004
Remyelination needs three things at once: a closed barrier, a cholesterol budget, and a sleep and immune window. Statins cut the budget. DKA, chemo, and sleep apnea open the barrier. APOE4 and DHCR7 variants start you with a smaller budget. Anticholinergics and chronic THC scramble the signal to build. Age and myelin debris refuse the work order. Stack two or three and the shorts stay.
Frame
The usual blockers
Age after about 55, myelin debris and a dirty matrix, chronic inflammation or a leaky barrier, not enough cholesterol, and oxidative or mitochondrial failure in precursor cells.
Documented
Multiple sclerosis
The textbook case. Precursor cells often sit in the lesion and never finish differentiating. Age and disease duration both cut repair. Cortical lesions remyelinate better than white-matter lesions.
Documented
Neuromyelitis optica spectrum
Antibody-driven astrocyte injury. Remyelination is secondary and often poor.
Documented
Leukodystrophies
Primary myelin or oligodendrocyte failure. Hundreds of genes. Not all of them are “myelin genes.” Diagnosis is an MRI pattern plus sequencing, not a vibe.
Documented
Stroke and prior ischemic injury
Barrier breakdown, fibrinogen in the tissue, and scar-matrix deposition. Fibrinogen itself blocks precursor differentiation through BMP signaling.
Documented
Diabetic ketoacidosis
Especially repeated or severe pediatric crises. Neutrophil enzymes chew tight junctions. Osmotic swings can produce osmotic demyelination. Oxidative stress in white matter is documented. The insult is the crisis and the barrier damage, not “statins causing DKA.”
Documented
Vitamin B12 deficiency
Including functional deficiency when the serum number looks normal. Methionine synthase fails, so myelin-protein methylation fails. Classic subacute combined degeneration.
Documented
Copper deficiency
Can mimic the myeloneuropathy of B12 deficiency.
Documented
Hypothyroidism
Thyroid hormone is a master differentiation signal for precursor cells. Low T3 or T4 slows the whole cascade.
Plausible
Familial hypercholesterolemia
LDL-receptor knockout animals show barrier leak, neuroinflammation, and early cognitive change. A large Norwegian human study found no extra dementia risk and no statin–dementia signal in FH. Treat as cardiovascular comorbidity, not a proven myelin-repair killer.
Plausible
APOE4, Alzheimer’s, and vascular cognitive impairment
APOE4 holds cholesterol inside oligodendrocytes instead of sending it into myelin, and it weakens the barrier. Human statin data in E4 carriers is mixed to protective for dementia risk. That does not prove myelin is unharmed. Mechanism and outcome can diverge.
Plausible
Sleep apnea and chronic REM loss
Glymphatic clearance and precursor proliferation both run during sleep. REM correlates with that proliferation. Chronic loss means thinner myelin and a repair window that never opens.
Plausible
Obesity, metabolic syndrome, insulin resistance
Chronic inflammation, barrier strain, and possible brain insulin resistance. Indirect, and common.
Weak / mixed
Depression, anxiety, and stress alone
Weak as a remyelination claim. They travel with sleep loss, inflammation, and medications. Do not list them as primary myelin toxins.
Documented
Statins, especially lipophilic ones
HMG-CoA reductase inhibitors. Simvastatin, lovastatin, and atorvastatin are the lipophilic set. Brain cholesterol is made locally. Simvastatin impairs remyelination after chemical demyelination in animals. Turnover is slow, about 0.02 percent a day, so the risk framed here is chronic use plus a second insult, not a weekend of Lipitor. Cochrane 2016 and HOPE-3 did not show population-level cognitive harm. Muldoon 2004 is the small-trial decline. Frame it as repair-budget suppression, not “statins melt brains.”
Documented
Methotrexate
Persistent precursor depletion, thinner myelin, and microglia-driven astrocyte activation. Wiping microglia in mice reversed the myelin and cognitive hit. Human brains after chemo show fewer Olig2-positive cells.
Documented
5-fluorouracil
Kills precursor cells and mature oligodendrocytes at concentrations relevant to cerebrospinal fluid. Delayed, progressive myelin destruction in mice.
Documented
Cisplatin, other platinums, BCNU, cytarabine
More toxic to neural progenitors and non-dividing oligodendrocytes than to many cancer lines. Cisplatin produces myelin decompaction.
Documented
Combination chemo regimens
CMF and FAC: cyclophosphamide plus methotrexate plus 5-FU, with or without doxorubicin. Decreased remyelination, stalled precursors, and myelin decompaction.
Documented
Anti-TNF biologics
Infliximab especially, also adalimumab and etanercept. Soluble TNF through TNFR1 is inflammatory. Membrane TNF through TNFR2 is needed for remyelination. Non-selective blockade can trigger central or peripheral demyelination. Rare, real, and labeled.
Documented
Immune checkpoint inhibitors
Can unmask autoimmune demyelination.
Documented
Rebound after some MS drugs
Fingolimod or natalizumab withdrawal. Lymphocytes re-entering can produce explosive demyelination. That is iatrogenic rebound, not a myelin toxin while the person is still on the drug.
Documented
First-generation antihistamines
Diphenhydramine and hydroxyzine. They cross the barrier, carry a high anticholinergic burden, and are associated with brain atrophy and dementia risk at cumulative dose. Diphenhydramine’s sigma-1 antagonism disrupts neuronal cholesterol trafficking. The myelin link is indirect. Stacked with a statin, synthesis is down and trafficking is down.
Documented
Other high-anticholinergic drugs
Older bladder drugs such as oxybutynin, some tricyclic antidepressants, and some antipsychotics. Same signaling problem for oligodendrocytes that need cholinergic cues. Cognitive burden is the documented part. The myelin link is indirect.
Weak / mixed
Topiramate
Do not overclaim. Cognitive dulling, word-finding trouble, and paresthesias are well documented. The oligodendrocyte literature goes the other way: AMPA and kainate blockade, and protection of pre-myelinating oligodendrocytes in hypoxic-ischemic white-matter models. Flag it as a cognitive-burden drug, not a myelin-synthesis blocker.
Weak / mixed
Antipsychotics
Haloperidol can increase precursor proliferation but inhibit differentiation into myelinating cells. Atypical agents are mixed. Some muscarinic antagonists, including clemastine, benztropine, and quetiapine, promote differentiation in screens.
Weak / mixed
Corticosteroids
Clobetasol showed up as a remyelination promoter in drug screens. Chronic systemic steroids are a different story: metabolism, sleep, and mood.
Weak / mixed
Amiodarone, metronidazole, some antibiotics
Toxic leukoencephalopathy shows up in case literature. Not a clean remyelination-failure class.
Documented
Heavy or early-onset cannabis (THC)
Thirty diffusion-MRI studies, about 1,457 users: lower fractional anisotropy in the corpus callosum and superior longitudinal fasciculus. Earlier onset is worse. Oligodendrocytes express CB1 and CB2. Developmental THC can promote myelination in animals. Chronic adolescent or adult use disrupts it. Years of daily use have case-level toxic leukoencephalopathy. Edibles count: the liver makes 11-hydroxy-THC, which crosses the barrier more efficiently than smoked THC.
Documented
Alcohol
White-matter atrophy, thinner myelin, fewer mature oligodendrocytes. Fetal and third-trimester models show large drops in precursors and mature cells. Some fractional-anisotropy studies show no clear recovery with abstinence.
Documented
Nicotine and tobacco nitrosamine
NNK thins myelin. Alcohol plus NNK is synergistic. Lifetime smoking associates with lower fractional anisotropy independent of other drugs.
Documented
Nitrous oxide
Whippets or heavy dental exposure. Oxidizes B12 into a functional deficiency even when the serum level looks normal. Demyelination of the dorsal columns. Supplements do not protect if use continues.
Documented
Lead
Delays precursor differentiation, disrupts myelin ultrastructure, and hits barrier endothelium.
Documented
Aluminum
A neurotoxin, elevated in some MS brain samples, with common exposure from water, additives, and some pharmaceuticals. The mechanism is oxidative stress, barrier injury, and possible autoimmunity, not a single enzyme block. Chelation is a physician decision, not a home protocol.
Documented
Mercury and other potentially toxic elements
Found in MS white matter more often than in controls in one autopsy series. Oligodendrocyte toxicity is plausible.
Plausible
Nutritional ketosis is not DKA
Crisis-level ketones are oxidative and hard on endothelium. Nutritional ketosis is not diabetic ketoacidosis. A brain held glucose-starved for a long time can lose metabolic flexibility. Slamming carbohydrates back onto a damaged barrier is a different insult than “butter is poison.” This is a plausible personal mechanism, not a published law that keto destroys myelin.
Plausible
Methamphetamine and cocaine
Excess dopamine is an oxidative load on oligodendrocytes. White-matter injury is documented in use disorders.
Plausible
Endocrine disruptors
BPA, some pesticides, and persistent organics. Animal and developmental myelin effects exist. Human remyelination data is thin.
Weak / mixed
Caffeine and CBD-dominant products
Do not list moderate coffee as a primary remyelination toxin. CBD-dominant products without heavy THC are not the same signal as chronic THC.
Documented
Pelizaeus–Merzbacher disease
PLP1, X-linked. The prototype hypomyelinating leukodystrophy.
Documented
Pelizaeus–Merzbacher-like disease
GJC2, also called connexin 47.
Documented
POLR3-related leukodystrophy
POLR3A, POLR3B, POLR1C. Also called 4H: hypomyelination, hypodontia, hypogonadism. A transcription-machinery disease.
Documented
TUBB4A (H-ABC)
Microtubules in the sheath.
Documented
SOX10 and NKX6-2
Transcription factors for oligodendrocytes.
Documented
FAM126A
Hypomyelination with congenital cataract.
Documented
Smith–Lemli–Opitz
DHCR7, the last step of cholesterol synthesis. Malformations, intellectual disability, and autism in a large fraction. In SLOS, Cochrane found insufficient statin benefit and a signal for more adverse reactions. Heterozygous or hypomorphic sterol-gene variants may affect about 3 percent of people and raise vulnerability to any sterol-blocking drug.
Documented
Other sterol-synthesis disorders
Desmosterolosis (DHCR24), lathosterolosis (SC5D), and CHILD or CDPX2 (NSDHL, EBP). Same pathway, different enzymes.
Documented
APOE4 as the common genetic hit
Common and semidominant. Cholesterol trapped in oligodendrocytes, hypomyelination, and a leaky barrier. Not a leukodystrophy. It is the population-level genetic hit.
Documented
Lipid storage and trafficking leukodystrophies
Metachromatic leukodystrophy (ARSA), Krabbe (GALC), Canavan (ASPA), X-linked adrenoleukodystrophy (ABCD1), Zellweger and other PEX genes, and Niemann–Pick C, where cholesterol trafficking fails and hypomyelination is secondary.
Documented
Vanishing white matter
EIF2B1 through EIF2B5. Translation stress. White matter melts under fever or other stress.
Documented
Megalencephalic leukoencephalopathy with cysts
MLC1.
Documented
Aicardi–Goutières
An interferonopathy. White matter plus inflammation.
Documented
Charcot–Marie–Tooth
Peripheral myelin, listed because many chemo agents that hit central myelin are also toxic in CMT, including vincristine and taxanes. Different compartment, same vulnerability logic.
Documented
Age
Remyelination is best under 55 and in the first decade of an MS-like injury. Aged precursor cells ignore differentiation cues.
Documented
Myelin debris
Contains MAG, Nogo-A, and OMgp. Blocks maturation until microglia clear it.
Documented
Extracellular matrix inhibitors
Hyaluronan, CSPGs, and fibrinogen from a leaky barrier.
Documented
Built-in brakes on differentiation
LINGO-1, Notch, Wnt and beta-catenin, and semaphorin 3A. This is why anti-LINGO trials existed.
Documented
Chronic sleep loss
About 4.5 days of deprivation thinned myelin roughly 8 percent in mice. Thirty-two hours of recovery did not restore thickness. Sleep-loss oligodendrocytes show endoplasmic-reticulum stress and cholesterol-transport failure. Boosting cholesterol transport into the sheath prevented the conduction and behavior hit in a 2026 PNAS paper. That is the cleanest mechanistic rhyme with statins in this list.
Documented
Oxidative stress in precursor cells
Precursors are more oxidatively fragile than mature oligodendrocytes. Reactive oxygen species upregulate Id2 and Id4 and block differentiation. Low glutathione sits in the same pile.
Documented
A barrier opened from any cause
Stroke, DKA, chemo, APOE4, inflammation, sleep loss. Opening the gate is one injury. Everything else keeps it from closing.
Plausible
A stack, not a single bullet
No single item has to “cause it.” Chemo, a long statin course, a cognitive-burden drug, lost REM, and metabolic inflexibility can cut the repair budget from several directions at once. That is the comorbidity thesis, not a courtroom autopsy.
Do not say
No dedicated DOJ myelin case
Do not say statins have a dedicated Department of Justice myelin case. This search did not find one. Nearby cases, on the money cards, are about promotion, delayed results, or generic delay. None of them is a myelin case.
Do not say
The Cuba quota is not documented
Do not say it is. It isn’t, on this record.
Do not say
Topiramate is not methotrexate
Do not say Topamax strips myelin the way methotrexate does. Current evidence does not say that.
Do not say
Nutritional ketosis is not DKA
Different dose, different acidity, different outcome. Do not equate them.
Do not say
APOE4 plus a statin is not proven brain damage
Some E4 data goes the other way on dementia incidence. Do not state it as proven injury.